Environmentally Sustainable Health Systems in Canada

RATIONALS

The Canadian Medical Association (CMA) has continually advocated for a healthy environment and sustainable health systems. These efforts are rooted in the belief that the health of the environment and human health are inextricably linked. Research has consistently shown that environmental factors play a significant role in the prevention and treatment of various health conditions. Addressing environmental issues can lead to improved health outcomes and reduced healthcare costs. Therefore, the CMA advocates for policies and practices that support a sustainable and healthy environment.

The CMA Policybase - Canadian Medical Association

CMA Policy

Environmentally Sustainable Health Systems in Canada

RATIONALS

The Canadian Medical Association (CMA) has continually advocated for a healthy environment and sustainable health systems. These efforts are rooted in the belief that the health of the environment and human health are inextricably linked. Research has consistently shown that environmental factors play a significant role in the prevention and treatment of various health conditions. Addressing environmental issues can lead to improved health outcomes and reduced healthcare costs. Therefore, the CMA advocates for policies and practices that support a sustainable and healthy environment.

Documents
CMA 2023 Pre-budget Submission to the House of Commons Standing Committee on Finance
https://policybase.cma.ca/link/policy14490

POLICY TYPE: Parliamentary submission
DATE: 2022-10-06
TOPICS: Health systems, system funding and performance
        Health human resources
        Population health, health equity, public health

Documents
CMA Recommendations on Canada’s First National Adaptation Strategy: Addressing the health impacts of climate change
https://policybase.cma.ca/link/policy14484

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2022-06-23</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Population health, health equity, public health Health systems, system funding and performance</td>
</tr>
</tbody>
</table>

Documents
CMA Letter to the Council of the Federation regarding the Council of the Federation meeting and Canada’s health funding priorities (health workforce, primary care, labour mobility)

https://policybase.cma.ca/link/policy14486

POLICY TYPE
Parliamentary submission

DATE
2022-06-22

TOPICS
Health systems, system funding and performance
Health human resources

Documents
Appearance before the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy14475

POLICY TYPE  Parliamentary submission
DATE  2022-05-09
TOPICS  Health systems, system funding and performance
Ethics and medical professionalism

Documents

Appearance before the House of Commons Standing Committee on Health

Dr. Katharine Smart
President of the Canadian Medical Association
May 9, 2022

(Canadian Medical Association logo)
Health Human Resource Policy Recommendations: Summary. Briefing to the House of Commons Standing Committee on Health
https://policybase.cma.ca/link/policy14473

POLICY TYPE  Parliamentary submission
DATE  2022-04-14
TOPICS  Health systems, system funding and performance
         Ethics and medical professionalism

Documents
Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities

https://policybase.cma.ca/link/policy14472

POLICY TYPE
Parliamentary submission

DATE
2022-03-28

TOPICS
Health human resources
Health systems, system funding and performance

Documents

Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities

Dr. Kathleen Swink
President of the Canadian Medical Association
March 28, 2022

(Handwritten text not visible)
Federal Policy Options to Advance Pan-Canadian Licensure
https://policybase.cma.ca/link/policy14471

POLICY TYPE
Parliamentary submission

DATE
2022-02-22

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents
Study on Canada’s Health Workforce
https://policybase.cma.ca/link/policy14469

POLICY TYPE
Parliamentary submission

DATE
2022-02-16

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents

Appearance before the House of Commons Standing Committee on Health:

Study on Canada’s Health Workforce

Dr. Kerrlene Smart
President of the Canadian Medical Association
February 16, 2022
Devoted to serving Canada
Recommendations for federal action to address Canada’s health care crisis
https://policybase.cma.ca/link/policy14468

POLICY TYPE
Parliamentary submission

DATE
2022-02-15

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents
Disclosure of COVID-19 Vaccination Status by Physicians

In the interim recommendations:

1. The Federal government recognizes that physicians will need to be informed about the status of COVID-19 vaccination of their patients. Physicians should not be required to disclose the status of COVID-19 vaccination of their patients.

2. Electronic medical record systems should allow physicians to indicate the status of COVID-19 vaccination of their patients.

3. Physicians should be able to provide written confirmation of the status of COVID-19 vaccination of their patients, if requested by a patient.

4. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

5. Physicians should be able to provide written confirmation of the status of COVID-19 vaccination of their patients, if requested by a third party.

6. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

7. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

8. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

9. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

10. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

11. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

12. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

13. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

14. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

15. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

16. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

17. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

18. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

19. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

20. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

21. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

22. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

23. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

24. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

25. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

26. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

27. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

28. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

29. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

30. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

31. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

32. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

33. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

34. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

35. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

36. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

37. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

38. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

39. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

40. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

41. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

42. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

43. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

44. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

45. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

46. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

47. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

48. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

49. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.

50. The physician should be informed by the patient's employer or insurance company if they are required to disclose the status of COVID-19 vaccination of their patients.
COVID-19 Vaccine Global Intellectual Property Policy
https://policybase.cma.ca/link/policy14458

POLICY TYPE  Policy document
DATE       2021-10-22
TOPICS     Physician practice, compensation, forms

COVID-19 Vaccine Global Intellectual Property Policy

Policy position recommendation

1. The CMA encourages the Government of Canada to participate in the global dialogue, led by the World Health Organization, the World Trade Organization, physicians, and the World Intellectual Property Organization, to ensure equitable access to COVID vaccines.

2. The CMA encourages the Government of Canada to support temporary, multilateral intellectual property (IP) waivers for COVID vaccines under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and their implementation.

3. The CMA supports the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

4. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

5. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

6. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

7. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

8. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

9. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

10. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

11. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

12. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

13. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

14. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

15. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

16. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

17. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

18. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

19. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

20. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

21. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

22. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

23. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

24. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

25. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

26. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

27. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

28. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

29. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.

30. The CMA encourages the Government of Canada to support the development and implementation of a comprehensive framework that ensures that intellectual property rights do not hinder access to COVID-19 vaccines, treatments, and technologies.
CMA 2022 Pre-Budget Submission
https://policybase.cma.ca/link/policy14445

POLICY TYPE: Parliamentary submission
DATE: 2021-08-05
TOPICS: Health systems, system funding and performance

Documents
CMA Letter – Bill C-30 Implementation

https://policybase.cma.ca/link/policy14442

POLICY TYPE
Parliamentary submission

DATE
2021-06-24

TOPICS
Health systems, system funding and performance

Documents
Consensus statement on networks for high-quality rural anesthesia, surgery, and obstetric care in Canada

https://policybase.cma.ca/link/policy14477

POLICY TYPE
Policy endorsement

DATE
2021-05-17

TOPICS
Health systems, system funding and performance
Health human resources
Learning from the pandemic – Transforming and improving Quebec’s health care system
https://policybase.cma.ca/link/policy14388

POLICY TYPE
Parliamentary submission

DATE
2021-01-21

TOPICS
Health systems, system funding and performance

Documents
Closing the Gaps: Advancing Emergency Preparedness, Response and Recovery for Older Adults
https://policybase.cma.ca/link/policy14384

POLICY TYPE  Policy endorsement
DATE  2020-12-15
TOPICS  Population health, health equity, public health
  Health systems, system funding and performance

Documents
National Standards for Long-Term Care: The art of the possible?
https://policybase.cma.ca/link/policy14383

POLICY TYPE
Policy endorsement

DATE
2020-12-08

TOPICS
Population health, health equity, public health
Health systems, system funding and performance
Committee Appearance: House of Commons Standing Committee on Health (HESA)
https://policybase.cma.ca/link/policy14381

POLICY TYPE: Parliamentary submission
DATE: 2020-11-30
TOPICS: Health systems, system funding and performance

Documents